NCT07203846View on ClinicalTrials.gov

Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
ACS - Acute Coronary SyndromeTicagrelorMicrobiotaPlatelet AggregationMyocardial Infarction (MI)Blood PlateletsDrug EffectsPlatelet Aggregation InhibitorsDrug ResistancePlatelet Function TestsDysbiosisAnti-Bacterial AgentsRifaximin
Interventions
DRUG

Rifaximin

Participants receiving a 7-day course of oral rifaximin 400 mg every 12 hours

Trial Locations (1)

85-094

Cardiology Department, Dr. A. Jurasz University Hospital, Bydgoszcz

All Listed Sponsors
collaborator

Ministry of Science and Higher Education, Poland

OTHER_GOV

lead

Collegium Medicum w Bydgoszczy

OTHER